Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination

Gelbenegger, Georg; Cacioppo, F; Firbas, Christa; Jilma, Bernd

doi:10.3390/vaccines9090956

Cited by 22 publications

(23 citation statements)

References 21 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Third, her weakness might have been due to myositis. Antibodies targeting skeletal muscle cells might have been generated, leading to myositis [18]. Although this could cause diffuse hyperintensity of the muscles, as was seen in our case, it was too fast to improve the abnormalities without immunotherapy, and myositis-associated antibodies were negative in our patient.…”

Section: Discussionmentioning

confidence: 57%

“…Fourth, her weakness could have been due to rhabdomyolysis caused by immunological responses triggered by the COVID-19 mRNA vaccinations. In this situation, myotoxic cytokines might have been released [18]. The first COVID-19 mRNA vaccination primes the innate immune system to mount a more potent response after the second booster immunization [19].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Recurring Weakness in Rhabdomyolysis Following Pfizer–BioNTech Coronavirus Disease 2019 mRNA Vaccination

2022

View full text Add to dashboard Cite

Rhabdomyolysis is a well-known clinical syndrome of muscle injury. Rhabdomyolysis following coronavirus disease 2019 (COVID-19) vaccination has recently been reported. The patients’ weakness gradually subsided and did not recur. Rhabdomyolysis associated with COVID-19 vaccination has not been assessed by repeated magnetic resonance imaging (MRI) within a short time. We report a rare case of an older woman who developed recurring weakness with rhabdomyolysis after COVID-19 vaccination. A 76-year-old woman presented with myalgia 2 days after receiving a third dose of the COVID-19 vaccine. A physical examination showed weakness of the bilateral iliopsoas muscles. Her creatine kinase concentration was 9816 U/L. MRI showed hyperintensity of multiple limb muscles. She was treated with intravenous normal saline. Her symptoms disappeared within 3 days. However, MRI on day 4 of hospitalization showed exacerbation of the hyperintensity in the left upper limb muscles. On day 5 of hospitalization, weakness of the left supraspinatus and deltoid muscles appeared. MRI on day 8 of hospitalization showed attenuation of the hyperintensity in all muscles. Her weakness and elevated creatine kinase concentration disappeared by day 10. Repeated MRI over a short time may be useful to predict potential weakness and monitor the course of COVID-19 vaccine-induced rhabdomyolysis.

show abstract

Section: Discussionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Recurring Weakness in Rhabdomyolysis Following Pfizer–BioNTech Coronavirus Disease 2019 mRNA Vaccination

2022

View full text Add to dashboard Cite

show abstract

“…This association has not been reported solely with the Pfizer-BioNTech COVID-19 vaccine as there was a case of rhabdomyolysis described in New Jersey, United States, following administration of the Ad26.COV2.S COVID-19 vaccine. 8 A 19-year-old male patient noted myalgia, muscle weakness, and darkened urine 2 days following his Ad26.COV2.S (Johnson & Johnson) COVID-19 vaccination. Laboratory evaluation revealed an increased CK of 15 638 U/L (peak of 44 180 U/L) and a urinalysis was positive for blood consistent with rhabdomyolysis.…”

Section: Discussionmentioning

confidence: 99%

A Possible Case of COVID-19 Booster Vaccine–Associated Rhabdomyolysis and Acute Kidney Injury

Unger

Ponte

Anderson

2022

Journal of Pharmacy Technology

View full text Add to dashboard Cite

Background: Nearly 10 billion doses of the various messenger ribonucleic acid (mRNA) and viral vector vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been administered worldwide. Adverse drug reactions (ADRs) have been overwhelmingly mild to moderate in nature. Rare side effects have included myocarditis/pericarditis, thrombosis with thrombocytopenia syndrome (TTS), Guillain-Barré Syndrome (GBS), and death. However, vaccine-related ADR data are still being collected using a variety of reporting systems. Purpose: We will describe a case of suspected mRNA coronavirus disease 2019 (COVID-19) booster–related rhabdomyolysis in a woman who developed signs and symptoms 10 days after administration of the vaccine dose. With a Naranjo ADR probability score of 4, the vaccine was deemed to be a possible cause of our patient’s rhabdomyolysis. Methods: A search of the VAERS (Vaccine Adverse Event Reporting System) mined in November 2021 revealed 386 reported cases of COVID-19 vaccine–related rhabdomyolysis. However, system limitations make the utility of the information problematic. Conclusions: It is vitally important that clinicians, scientists, and patients are aware of rhabdomyolysis as a potential side effect of vaccination. Suspected vaccine-related ADRs should be promptly and accurately reported via VAERS or other surveillance systems to support the ongoing effort to ensure vaccine safety.

show abstract

“…Post-mortem investigations were not performed. Other cases of rhabdomyolysis after COVID-19 vaccination have been reported, both in the literature and in the side effects reporting systems (e.g., VAERS) [101][102][103][104][105][106][107][108][109]. Again, it is difficult to assess whether the link between the rhabdomyolysis is causal or only temporal and the diagnosis of vaccine-induced rhabdomyolysis is based on the exclusion of other causes.…”

Section: Rhabdomyolysismentioning

confidence: 99%

Death after the Administration of COVID-19 Vaccines Approved by EMA: Has a Causal Relationship Been Demonstrated?

et al. 2022

View full text Add to dashboard Cite

More than eight billion doses of COVID-19 vaccines have been administered globally so far and 44.29% of people are fully vaccinated. Pre-authorization clinical trials were carried out and the safety of vaccines is still continuously monitored through post-commercialization surveillance. However, some people are afraid of vaccine side effects, claiming they could lead to death, and hesitate to get vaccinated. Herein, a literature review of COVID-19-vaccine-related deaths has been carried out according to the PRISMA standards to understand if there is a causal relationship between vaccination and death and to highlight the real extent of such events. There have been 55 cases of death after COVID-19 vaccination reported and a causal relationship has been excluded in 17 cases. In the remaining cases, the causal link between the vaccine and the death was not specified (8) or considered possible (15), probable (1), or very probable/demonstrated (14). The causes of deaths among these cases were: vaccine-induced immune thrombotic thrombocytopenia (VITT) (32), myocarditis (3), ADEM (1), myocardial infarction (1), and rhabdomyolysis (1). In such cases, the demonstration of a causal relationship is not obvious, and more studies, especially with post-mortem investigations, are needed to deepen understanding of the possible pathophysiological mechanisms of fatal vaccine side effects. In any event, given the scarcity of fatal cases, the benefits of vaccination outweigh the risks and the scientific community needs to be cohesive in asserting that vaccination is fundamental to containing the spread of SARS-CoV-2.

show abstract

Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination

Cited by 22 publications

References 21 publications

Recurring Weakness in Rhabdomyolysis Following Pfizer–BioNTech Coronavirus Disease 2019 mRNA Vaccination

Recurring Weakness in Rhabdomyolysis Following Pfizer–BioNTech Coronavirus Disease 2019 mRNA Vaccination

A Possible Case of COVID-19 Booster Vaccine–Associated Rhabdomyolysis and Acute Kidney Injury

Death after the Administration of COVID-19 Vaccines Approved by EMA: Has a Causal Relationship Been Demonstrated?

Contact Info

Product

Resources

About